Want to see IN:ZOTA full AI Analyst Report?
ZOTA Stock Chart & Stats
₹1533.20
₹23.30(2.41%)
At close: 4:00 PM EST
₹1533.20
₹23.30(2.41%)
Day’s Range― - ―
52-Week Range₹1,026.20 - ₹1,740.00
Previous CloseN/A
Volume255.13K
Average Volume (3M)68.23K
Market Cap
₹43.83B
Enterprise Value₹38.79B
Total Cash (Recent Filing)₹63.18M
Total Debt (Recent Filing)₹1.81B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.06%
Share Statistics
EPS (TTM)-16.69
Shares Outstanding30,332,655
10 Day Avg. Volume83,032
30 Day Avg. Volume68,228
Financial Highlights & Ratios
PEG Ratio-5.04
Price to Book (P/B)5.05
Price to Sales (P/S)6.51
P/FCF Ratio-18.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-20.3
Revenue Forecast (FY)₹11.08B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue has accelerated materially into 2025–2026, reflecting expanding market penetration and product traction. Durable top-line expansion supports scale economics, broader sales footprint and reinvestment potential if management reverses margin and cash-flow headwinds.
Diverse Product & Market ExposureA portfolio spanning branded and generic formulations across therapeutic areas and both domestic and export channels reduces concentration risk. This structural diversification supports steadier demand, cross-selling, and multiple routes to revenue growth over the medium term.
Moderate Leverage On PaperBalance sheet shows a substantially grown equity base and a debt-to-equity around 0.39 in 2026, implying manageable leverage on paper. This provides financial headroom to raise incremental capital or withstand cyclical pressure while executing operational fixes.
Bears Say
Severe Margin DeteriorationA dramatic collapse in gross and net margins signals structural pressure from pricing, mix shifts, or cost inflation that is eroding unit economics. Durable profitability recovery is required; otherwise continued losses will impede reinvestment and long-term value creation.
Persistent Cash BurnOperating and free cash flows are deeply negative, with FCF around -1.92B in 2026, indicating sustained cash burn. This forces reliance on external funding, increases execution risk, and limits ability to self-fund growth or absorb shocks over the coming quarters.
Rapidly Rising Debt Amid LossesDebt has increased sharply while the company remains loss-making and ROE is negative. Rising leverage alongside ongoing losses heightens refinancing and interest risks, constrains strategic flexibility, and could pressure liquidity if operational recovery lags.
Zota Health Care Ltd. News
ZOTA FAQ
What was Zota Health Care Ltd.’s price range in the past 12 months?
Zota Health Care Ltd. lowest stock price was ₹1026.20 and its highest was ₹1740.00 in the past 12 months.
What is Zota Health Care Ltd.’s market cap?
Zota Health Care Ltd.’s market cap is ₹43.83B.
When is Zota Health Care Ltd.’s upcoming earnings report date?
Zota Health Care Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 36 days.
How were Zota Health Care Ltd.’s earnings last quarter?
Zota Health Care Ltd. released its earnings results on May 22, 2026. The company reported -₹4.4 earnings per share for the quarter, beating the consensus estimate of -₹18.4 by ₹14.
Is Zota Health Care Ltd. overvalued?
According to Wall Street analysts Zota Health Care Ltd.’s price is currently Overvalued.
Does Zota Health Care Ltd. pay dividends?
Zota Health Care Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.06%. See more information on Zota Health Care Ltd. dividends here
What is Zota Health Care Ltd.’s EPS estimate?
Zota Health Care Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zota Health Care Ltd. have?
Zota Health Care Ltd. has 30,332,655 shares outstanding.
What happened to Zota Health Care Ltd.’s price movement after its last earnings report?
Zota Health Care Ltd. reported an EPS of -₹4.4 in its last earnings report, beating expectations of -₹18.4. Following the earnings report the stock price went down -1.949%.
Which hedge fund is a major shareholder of Zota Health Care Ltd.?
Currently, no hedge funds are holding shares in IN:ZOTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zota Health Care Ltd.
Zota Health Care Limited is an Indian pharmaceutical firm dedicated to the development, manufacturing, and distribution of a broad spectrum of health-related products across India. Its extensive portfolio encompasses generic medications, over-the-counter (OTC) remedies, traditional Ayurvedic formulations, and nutritional supplements (nutraceuticals). The company places a particular emphasis on supplying treatments for various long-term illnesses, including but not limited to heart disease, diabetes, and thyroid conditions. By March 31, 2021, Zota had established a considerable retail network, operating 591 stores under its DAVAINDIA brand name throughout 24 states in India. The company was founded in 1995 and is currently headquartered in Surat, India.
Technical Analysis
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Supriya Lifescience Limited
―
OneSource Specialty Pharma Limited
―